Hims & Hers Health (NYSE:HIMS) versus MDxHealth (NASDAQ:MDXH) Head-To-Head Comparison

Hims & Hers Health (NYSE:HIMS) and MDxHealth (NASDAQ:MDXH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Risk & Volatility

Hims & Hers Health has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Hims & Hers Health and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	3	7	2	0	1.92
MDxHealth	0	0	3	0	3.00

Hims & Hers Health presently has a consensus price target of $39.8333, indicating a potential downside of 13.57%. MDxHealth has a consensus price target of $7.00, indicating a potential upside of 145.61%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Hims & Hers Health.

Earnings and Valuation

This table compares Hims & Hers Health and MDxHealth”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$1.48 billion	7.06	$126.04 million	$0.80	57.61
MDxHealth	$90.05 million	1.50	-$38.07 million	($0.88)	-3.24

Hims & Hers Health has higher revenue and earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hims & Hers Health and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	9.63%	26.26%	13.06%
MDxHealth	-34.98%	-274.67%	-21.21%

Institutional and Insider Ownership

63.5% of Hims & Hers Health shares are owned by institutional investors. 17.7% of Hims & Hers Health shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Hims & Hers Health beats MDxHealth on 11 of the 14 factors compared between the two stocks.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.